OOIR: Observatory of International Research

Papers

(The TQCC of Hematology-Oncology Clinics of North America is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
Epidemiology of Melanoma	47
Molecular Pathogenesis of Mantle Cell Lymphoma	44
Biology of Melanoma	42
Screening for Colorectal Cancer	38
Diagnosis and Staging of Bladder Cancer	36
Factor XI Deficiency	35
The Epidemiology of Bladder Cancer	29
Epidemiology of Follicular Lymphoma	22
Nasopharyngeal Carcinoma and Its Association with Epstein-Barr Virus	22
Lip and Oral Cavity Squamous Cell Carcinoma	20
Overview of Myeloproliferative Neoplasms	19
Blastoid Mantle Cell Lymphoma	19
Immunotherapies Targeting CD123 for Blastic Plasmacytoid Dendritic Cell Neoplasm	19
Disorders of Fibrinogen and Fibrinolysis	18
Current Role and Emerging Evidence for Bruton Tyrosine Kinase Inhibitors in the Treatment of Mantle Cell Lymphoma	17
CD123 as a Therapeutic Target Against Malignant Stem Cells	17
Colorectal Cancer in Younger Adults	17
Epidemiology of the Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms	16
Von Willebrand Disease	16
The Epidemiology of Central Nervous System Tumors	14
Hereditary Colorectal Cancer	14
Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm	14
Genetics of Myeloproliferative Neoplasms	14
Blastic Plasmacytoid Dendritic Cell Neoplasm in Children	14
Rare Coagulation Factor Deficiencies (Factors VII, X, V, and II)	13

Acquired von Willebrand Syndrome	13
The Role of Megakaryocytes in Myelofibrosis	13
Tagraxofusp for Blastic Plasmacytoid Dendritic Cell Neoplasm	13
Molecular Features of Blastic Plasmacytoid Dendritic Cell Neoplasm	13
Blastic Plasmacytoid Dendritic Cell Neoplasm	13
Racial and Ethnic Disparities in Colorectal Cancer Screening and Outcomes	13
Current Therapy and Emerging Intravesical Agents to Treat Non–Muscle Invasive Bladder Cancer	12
Gene Therapy for Hemoglobinopathies	12
Hematopoietic Cell Transplant for Blastic Plasmacytoid Dendritic Cell Neoplasm	12
The Microenvironment in Myeloproliferative Neoplasms	12
Pancreatic Adenocarcinoma	11
Current Clinical Investigations in Myelofibrosis	11
Acquired Hemophilia A	11
Cellular Therapy and Cytokine Treatments for Melanoma	11
Impact of Diet and Exercise on Colorectal Cancer	10
Central Nervous System Metastases	10
Developing Precision Medicine for Bladder Cancer	10
Primary Central Nervous System Lymphomas	10
Minimal Residual Disease in Mantle Cell Lymphoma	9
A Curative DNA Code for Hematopoietic Defects	9
Managing Recurrent Metastatic Head and Neck Cancer	9
Cancer of the Paranasal Sinuses	9
Neurocognition and Health-Related Quality of Life Among Patients with Brain Tumors	9
Immunotherapy for Head and Neck Cancer	9
Structural Racism and Impact on Sickle Cell Disease	9
Systemic Amyloidosis Due to Clonal Plasma Cell Diseases	8
Updates on the Diagnosis and Management of Cold Autoimmune Hemolytic Anemia	8
Should Undetectable Minimal Residual Disease Be the Goal of Chronic Lymphocytic Leukemia Therapy?	8
Preclinical Models for Bladder Cancer Research	8
Factor XIII Deficiency	8
Contemporary and Emerging Approaches to Bladder-Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer	8
Chemotherapy Options for Blastic Plasmacytoid Dendritic Cell Neoplasm	8
Systemic Amyloidosis due to Low-Grade Lymphoma	8
Gene Therapy and Gene Editing for β-Thalassemia	8
Go the Distance	8
Monoclonal Antibody Therapies in Systemic Light-Chain Amyloidosis	8
The Process of Amyloid Formation due to Monoclonal Immunoglobulins	8
Salivary Gland Cancers	8
Thrombotic, Vascular, and Bleeding Complications of the Myeloproliferative Neoplasms	7
Cancer of the Larynx and Hypopharynx	7
Neurofibromatoses	7
Hemophilia A (Factor VIII Deficiency)	7
Stem Cell Mobilization and Autologous Transplant for Immunoglobulin Light-Chain Amyloidosis	7
Update on Radiation Therapy for Central Nervous System Tumors	6
Application of Single-Cell Approaches to Study Myeloproliferative Neoplasm Biology	6
Isocitrate Dehydrogenase Mutant Grade II and III Glial Neoplasms	6
The Clinical Phenotypes of Alpha Thalassemia	6
Management of Rectal Cancer	6
Autoimmune Hemolytic Anemia: Diagnosis and Differential Diagnosis	6
Renal Cell Carcinoma of Variant Histology	6

Application of Stem Cell Therapy in Myelofibrosis	6
Hemophilia B (Factor IX Deficiency)	6
Imaging Advances for Central Nervous System Tumors	6
Adult Evans' Syndrome	6
Watch and Wait in Mantle Cell Lymphoma	6
Allogeneic Transplantation and Chimeric Antigen Receptor-Engineered T-Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma	6
Chimeric Antigen Receptor T-cell Therapy	6
Cell Cycle Dysregulation in Mantle Cell Lymphoma	6
Potential Relevance of B-cell Maturation Pathways in Defining the Cell(s) of Origin for Chronic Lymphocytic Leukemia	6
The Evolving Use of Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Chronic Lymphocytic Leukemia	6
Real World Outcomes of Patients with Bladder Cancer	6
Systemic Amyloidosis Caused by Monoclonal Immunoglobulins	5
The Clinical Utility of ESR1 Mutations in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer	5
Liver and Gastrointestinal Involvement	5
Gene Therapy for Inborn Errors of Immunity	5
Fetal Hemoglobin Regulation in Beta-Thalassemia	5
Advanced Melanoma	5
Disparities and Inequities Among Patients with Central Nervous System Tumor	5
The Biological Basis of Histologic Transformation	5
Nonoperative Management for Rectal Cancer	5
Molecular Basis and Genetic Modifiers of Thalassemia	5
Immune Therapy for Chronic Lymphocytic Leukemia	5
Ex Vivo and In Vivo Gene Therapy for Mucopolysaccharidoses: State of the Art	5
Robotic and Endoscopic Approaches to Head and Neck Surgery	5
Is There a Role for Immunotherapy in Central Nervous System Cancers?	5
Evolution of Gene Therapy, Historical Perspective	5
Liver and Gastrointestinal Involvement	5
Combinatorial Approaches to the Treatment of Advanced Melanoma	5
Convergence of Precision Oncology and Liquid Biopsy in Non-Small Cell Lung Cancer	5
Accelerated and Blast Phase Myeloproliferative Neoplasms	4
Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia	4
Treatment of Histologic Transformation	4
Role of Ovarian Suppression in Early Premenopausal Breast Cancer	4
Epigenetic Dysregulation of Myeloproliferative Neoplasms	4
Emerging Targeted Therapy for Bladder Cancer	4
Current Therapy for Metastatic Urothelial Carcinoma	4
The Evolving Landscape of Drug Therapies for Sickle Cell Disease	4
Approach to the Initial Treatment of Older Patients with Mantle Cell Lymphoma	4
Supportive Care for Patients with Systemic Light Chain Amyloidosis	4
Systemic Amyloidosis due to Monoclonal Immunoglobulins	4
State of Melanoma	4
Biology and Treatment of Meningiomas	4
Quality of Life in Sickle Cell Disease	4
Surgical Management of the Axilla for Breast Cancer	4
Red Cell Antigens and Antibodies	4
Cancer of the Oropharynx and the Association with Human Papillomavirus	4
Immunotherapy-associated Autoimmune Hemolytic Anemia	4
Surgery for Bladder and Upper Tract Urothelial Cancer	4
Genetic Modifiers of Sickle Cell Disease	4
Immune Checkpoint Therapies for Melanoma	4
Blastic Plasmacytoid Dendritic Cell Neoplasm	4
Role of Immunotherapy in Early- and Late-Stage Triple-Negative Breast Cancer	4
Future Perspectives	4
Cytogenetics of Blastic Plasmacytoid Dendritic Cell Neoplasm	4
Emerging Therapies in β-Thalassemia	4
Quality of Life in Myeloproliferative Neoplasms	4
Hematopoietic Stem Cell Transplantation in Thalassemia	4
Molecular Biology of Bladder Cancer	4